share_log

Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82

Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82

Canaccord Genuity以持有評級啓動對Moderna的報道,宣佈目標股價爲82美元
Benzinga ·  2023/11/29 05:16

Canaccord Genuity analyst Bill Maughan initiates coverage on Moderna (NASDAQ:MRNA) with a Hold rating and announces Price Target of $82.

Canaccord Genuity分析師比爾·莫恩以持有評級開始對Moderna(納斯達克股票代碼:MRNA)進行報道,並宣佈目標股價爲82美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論